OrganaBio ads

Today we announced that OrganaBio has acquired the operating assets of Excellos. The combined company is now a coast-to-coast cell therapy CDMO with cGMP manufacturing, PBMC isolation, and cryopreservation services on both sides of the country. The industry has lived with a difficult trade-off for years. Working with a single partner concentrates risk, while splitting work across multiple partners introduces lot-to-lot variability, divergent quality systems, and inconsistent execution between sites. OrganaBio and Excellos together give cell therapy developers a way out of that trade-off: geographic redundancy and infrastructure depth inside one relationship, under one quality framework. With this acquisition our combined customer base spans many of the world's leading pharmaceutical and biotechnology developers, with programs concentrated in cancer and autoimmune indications. A lot of people made this happen. Thank you to the Excellos team for trusting us with what they've built, and to the OrganaBio team for the work that got us to today!

Most cell-therapy programs lose months looking for the right donor twice, once for development, again when scale-up demands a recallable match. We solve that on the front end. Single donors, deeply characterized, recallable on demand. We match. You research. OrganaBio runs its own collection sites, processing labs, and cryostorage, so when you ask for the same donor again at higher volume, the answer is yes, not maybe. Request a sample. Tell us the indication; we'll come back with donor profiles that fit.

Cryopreserved leukopaks, single-donor, fully characterized, sitting in your freezer for whenever the protocol fires. Most pharma teams underestimate the unlock here. When fresh isn't an option, a frozen leukopak that thaws to spec is the difference between running the assay this week or next quarter. Our frozen product is built for the second case, not the first. Same donor characterization. Same recallability. Designed for high post-thaw viability per validated protocol. Request a sample. Test the thaw before you commit a program to it.

One handoff. One miscommunication between collection, processing, and cryostorage. One vendor sub-contracting the actual work to someone you've never met. That's where most reproducibility problems start. Not in your lab. Upstream. OrganaBio does the whole chain in-house. Donor recruitment, apheresis, characterization, cryopreservation, ship. Same team. Same SOPs. Same accountability when something looks off in your assay. It's not the cheapest option. It's the one that doesn't cost you a quarter when you scale. Request a sample. See the COA before you commit.

The starting material decides what your program can do downstream. A pooled donor with no recall path. A leukopak that thawed below spec. A vendor that ships when they ship. Each one quietly limits what your program can do downstream, and you don't always feel it until later in the program. OrganaBio supplies single-donor, fully characterized leukopaks with known recallability, HLA typing, and same-team handling from collection to ship. One supply chain. No handoffs. No surprises in the COA. If your next milestone depends on the cells in the bag, the bag matters more than the price. Request a sample. We'll match you to the donor profile your protocol actually needs.

30 minutes from donor to processing. Custom collections to your protocol. Single-donor leukopaks, fully characterized with HLA typing and immune-cell counts, available fresh or cryopreserved. This is what ready when you are actually means in practice, not a marketing line, an SOP. If your team is still chasing aliquot consistency, donor variability, or the right freeze profile, you're solving the wrong problem. Solve it once at the source. Request a sample. We'll follow up with the COA and donor profile.